Interim results reflected the two sustained strategic themes for Tristel: (i) strong growth from its international markets (53% of revenues, growing at 23% CER or 16% ex-Ecomed acquisition); and (ii) growth in Human Healthcare (91% of revenues and rising 16% CER). The need to complete more extensive human usability studies to comply with the FDA de novo 510(k) filing process in the US has no real impact on our forecast horizon, with international markets more than offsetting the c.£50k
25 Feb 2019
Tristel - Interims underpin full-year outlook
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Tristel - Interims underpin full-year outlook
Tristel Plc (TSTL:LON) | 465 11.6 0.5% | Mkt Cap: 221.0m
- Published:
25 Feb 2019 -
Author:
Mark Brewer -
Pages:
13
Interim results reflected the two sustained strategic themes for Tristel: (i) strong growth from its international markets (53% of revenues, growing at 23% CER or 16% ex-Ecomed acquisition); and (ii) growth in Human Healthcare (91% of revenues and rising 16% CER). The need to complete more extensive human usability studies to comply with the FDA de novo 510(k) filing process in the US has no real impact on our forecast horizon, with international markets more than offsetting the c.£50k